Paper Details

  1. Home
  2. Paper Details

Double liposomes mediated dual drug targeting for treatment of Helicobacter pylori infections.

Author: PrasadN Kamta, SinghD Yuvraj

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explores the potential of phosphatidylethanolamine (PE) lipid anchored double liposomes (DL) as a dual-drug delivery system to enhance the eradication rate of H. pylori infections.
Paper Details　
Original Abstract of the Article :
In the present study the potential of phosphatidylethanolamine (PE) lipid anchored double liposomes (DL) to incorporate two drugs in a single system is exploited as a tool to augment the H. pylori eradication rate. Preparation of DL involves two steps, first formation of primary (inner) liposomes by...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21699071

データ提供：米国国立医学図書館（NLM）

Double Liposomes: A Dual-Drug Delivery System for Fighting Helicobacter pylori

Helicobacter pylori (H. pylori), a bacterium that colonizes the stomach, can cause a range of gastrointestinal disorders, including ulcers and gastritis. Effective eradication of H. pylori is essential for preventing these complications. This study explores the potential of double liposomes, a novel drug delivery system, to deliver two different drugs simultaneously, aiming to enhance the eradication rate of H. pylori infections.

Double Liposomes: A Targeted Approach to H. pylori Eradication

The study demonstrated that double liposomes could effectively encapsulate and deliver two drugs, amoxicillin trihydrate (AMOX) and ranitidine bismuth citrate (RBC), which are commonly used to treat H. pylori infections. The researchers observed a significant increase in the eradication rate of H. pylori when using this dual-drug delivery system. This suggests that double liposomes may offer a promising approach to improving the effectiveness of H. pylori eradication therapy.

A New Frontier in H. pylori Treatment: Double Liposomes

This study provides encouraging evidence for the potential of double liposomes as a targeted drug delivery system for H. pylori eradication. Further research is needed to optimize this approach and to evaluate its long-term efficacy and safety in clinical settings. This innovative strategy holds promise for improving the management of H. pylori infections and reducing the burden of associated gastrointestinal disorders.

Dr.Camel's Conclusion

This study, like a desert oasis providing a haven for travelers, presents a promising new approach to combatting H. pylori infections. Double liposomes offer a targeted and effective way to deliver multiple drugs, potentially increasing eradication rates and improving patient outcomes. We must continue to explore the potential of this innovative technology, seeking to refine its application and expand its impact in the fight against H. pylori infections.

Date :
  1. Date Completed 2011-07-18
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

21699071

DOI: Digital Object Identifier

21699071

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.